GDC-6036 Monotherapy Reveals Promising Activity in KRAS G12C–Mutant NSCLCAugust 7th 2022
A phase 1a trial of GDC-6036 showed encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.
Biomarker Testing in Lung Cancer Dependent on Type of Health InsuranceAugust 1st 2022
Cary Gross, MD, discusses the results of a retrospective study of patients with advanced non-small cell lung cancer that showed an association between Medicaid insurance, rates of biomarker testing, and patient outcomes.
Experts Anticipate New Results From Sotorasib for KRAS G12C+ NSCLCJuly 14th 2022
A highly anticipated presentation at the 2022 World Conference on Lung Cancer will be the first report of efficacy and safety from the phase 1b/2 CodeBreak 101 clinical trial and will provide updated results from the phase 2 CodeBreak 100 study.
Goals in the Phase 1 Study of a New RET Inhibitor for NSCLC and MTCJuly 9th 2022
Nathan A. Pennell, MD, PhD, discusses the study design and goals of an ongoing phase 1 trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.
Examining Trends of Biomarker Testing With the MYLUNG Study in mNSCLCJune 23rd 2022
During an interview with Targeted Oncology, Nicholas J. Robert, MD, further discussed the data of the MYLUNG study which he presented in a poster at the 2022 American Society of Clinical Oncology Annual Meeting.
Improved PFS With Toripalimab Plus Chemotherapy in NSCLC Regardless of PD-L1 StatusJune 13th 2022
Combination of toripalimab and chemotherapy in the frontline setting shows survival benefit in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.
Pembrolizumab Alone Shows Best Response in NSCLC With 90% or Higher PD-L1 ExpressionJune 7th 2022
Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.
Adagrasib Displays Encouraging Responses, Disease Control in KRAS G12C+ NSCLCJune 3rd 2022
Treatment with the KRAS G12C inhibitor adagrasib showed a promising objective response rate and disease control rate in patients with previously treated KRAS G12C–mutated non–small cell lung cancer.
Community Health Systems Test for Recommended Cancer Biomarkers More Often Than Independent PracticesMay 26th 2022
In patients with advanced non-squamous non–small cell lung cancer treated within large community health systems in the United States , biomarker testing appeared to be significantly higher compared with independent community practices, research shows.
Role of Molecular Biology, Evolving Immunotherapy Addressed in Lung Cancer ConferenceMay 22nd 2022
At the upcoming 23rd Annual International Lung Cancer Congress®, Solange Peters, MD, PhD will be giving two presentation around relevant biomarkers in perioperative immunotherapy and the role of treatment agent sequencing in ALK-rearranged non–small cell lung cancer.
Larotrectinib Efficacy Withstands Various NTRK Gene Fusions in Non-Primary CNS TRK Fusion+ CancerMay 1st 2022
In an interview with Targeted Oncology, Marc Ladanyi, MD, discussed pooled data of larotrectinib in patients with NTRK fusion-positive cancers and how variability in NTRK gene fusions impacts outcomes.
Overcoming MET TKI Resistance in Patients with Non–Small Cell Lung CancerApril 28th 2022
In an interview with Targeted Oncology™, Yonina R. Murciano-Goroff, MD, MSc, DPhil, discussed how MET fusions impact patients with NSCLC and the issue of resistance to targeted therapies that treat MET fusion-positive disease.